Astrego Diagnostics

About this entry

Astrego Diagnostics was created on a vision to enable personalised prescription of antibiotics guided by rapid and cost-effective susceptibility tests. Our ultra-rapid Antibiotic Susceptibility Test (AST) utilises patented technology developed in the lab of Prof. Johan Elf at Uppsala University for fundamental research on bacterial growth at the single-cell level. We are now developing the CaptiverTM system for use in near-patient settings together with multiplexed, single-use, test panels for different clinical applications - such as urinary tract infection (UTI).

Captiver uses cutting-edge microfluidics to capture and monitor bacterial growth from patient samples - in real-time. The test is truly phenotypic, being dependent on the characteristics of the actual bacteria present. The microfluidic technology reduces the time to result (TTR) to well under 1 hour compared with 48 hours for conventional methods, and 2-6 hours for emerging rapid ASTs. Astrego’s ultra-rapid AST will be game-changing, enabling susceptibility testing in near-patient and point of care (POC) settings. 

The Captiver UTI-panel will break the empirical paradigm for management of UTI patients, providing effective diagnosis and personalised antibiotic prescription at the first healthcare consultation. This will significantly improve patient outcomes and reduce antimicrobial resistance (AMR).
Astrego is an experienced team of engineers, scientists and diagnostic industry entrepreneurs with the skills needed to both develop and commercialise Captiver and the UTI-Panel. 

If you would like to be introduced to this team for collaboration, get in touch with the Longitude prize.